MODALITY HUB
FOR TREATMENT
现在就能报名的(招募中)排在最前,共 1 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.
Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.
Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers.
Virus infections and cancers: from mechanisms to therapeutics.
GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.
Optimized L1CAM-CAR T cells enhance activity against moderate-antigen-density rhabdomyosarcoma models.
A conceptual blueprint for "turning cold to hot" in Osteosarcoma: from TME stratification hypotheses to adaptive therapeutic prospects.
LRRC15-CAR T Cells for the Treatment of Osteosarcoma.
LRRC15-CAR-T 细胞在保持良好安全性特征的同时发挥抗骨肉瘤活性。
HIV-driven tumor ecosystem: from chronic immune dysfunction to cancer evolution.
MEMBER ACCOUNT
登录成功会直接打开下一页。